Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
INDERIDE LA 160/50 is a fixed-dose combination of propranolol (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic) in extended-release formulation. It is indicated for hypertension management by reducing blood pressure through dual mechanisms: beta-blockade and diuretic action. This combination is designed for adjunctive or maintenance therapy in patients requiring dual antihypertensive therapy.
As a product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle management and transition planning rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on INDERIDE LA offers limited career advancement opportunities due to its LOE-approaching status and minimal linked job openings. Professionals assigned to this product are typically focused on defending market share, managing generic transition, and ensuring compliance rather than driving innovation or commercial expansion.
Worked on INDERIDE LA 160/50 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.